More Articles Back to Article
EU approves anemia drug Reblozyl
The EU has approved Reblozyl, an erythroid maturation agent that treats anemia in patients with a rare blood cancer. The drug is manufactured by Bristol-Myers Squibb and was under development by Celegne before it merged with BMS. PMLive (UK) (6/29)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!